Search results
Results From The WOW.Com Content Network
The Kaplan–Meier estimator, [1] [2] also known as the product limit estimator, is a non-parametric statistic used to estimate the survival function from lifetime data. In medical research, it is often used to measure the fraction of patients living for a certain amount of time after treatment.
S(t) is theoretically a smooth curve, but it is usually estimated using the Kaplan–Meier (KM) curve. The graph shows the KM plot for the aml data and can be interpreted as follows: The x axis is time, from zero (when observation began) to the last observed time point. The y axis is the proportion of subjects surviving. At time zero, 100% of ...
The x-axis is time. The y-axis is the proportion of subjects surviving. The graphs show the probability that a subject will survive beyond time t. Four survival functions. For example, for survival function 1, the probability of surviving longer than t = 2 months is 0.37. That is, 37% of subjects survive more than 2 months. Survival function 1
Paul Meier (July 24, 1924 – August 7, 2011) [1] was a statistician who promoted the use of randomized trials in medicine. [2] [3]Meier is known for introducing, with Edward L. Kaplan, the Kaplan–Meier estimator, [4] [5] a method for measuring how many patients survive a medical treatment from one duration to another, taking into account that the sampled population changes over time.
There are several software suites available to estimate relative survival rates. Regression modelling can be performed using maximum likelihood estimation methods by using Stata or R. [4] [5] For example, the R package cmprsk may be used for competing risk analyses which utilize sub-distribution or 'Fine and Gray' regression methods. [6]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Kaplan-Meier_curve&oldid=301564058"
I beleive that an example calculation is necessary for a comprehensive description of the Kaplan-Meier estimate. However, I agree that the section is long, and it need not be in the middle of the article; it can be moved to the end for those readers who wish to see the example calculation.
An early paper to use the Kaplan–Meier estimator for estimating censored costs was Quesenberry et al. (1989), [3] however this approach was found to be invalid by Lin et al. [4] unless all patients accumulated costs with a common deterministic rate function over time, they proposed an alternative estimation technique known as the Lin ...